{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T20:52:43Z","timestamp":1791147163783,"version":"4.1.0"},"reference-count":268,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2012,7,1]],"date-time":"2012-07-01T00:00:00Z","timestamp":1341100800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,7,1]],"date-time":"2012-07-01T00:00:00Z","timestamp":1341100800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["pharmrev.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Reviews"],"published-print":{"date-parts":[[2012,7]]},"DOI":"10.1124\/pr.111.005587","type":"journal-article","created":{"date-parts":[[2012,7,3]],"date-time":"2012-07-03T05:44:56Z","timestamp":1341294296000},"page":"583-620","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":107,"title":["The Pharmacological Treatment of Pulmonary Arterial Hypertension"],"prefix":"10.1016","volume":"64","author":[{"given":"Lyn R.","family":"Frumkin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/pr.111.005587_bib1","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1165\/rcmb.2010-0371OC","article-title":"Tyrosine kinase inhibitors are potent acute pulmonary vasodilators in rats","volume":"45","author":"Abe","year":"2011","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1124\/pr.111.005587_bib2","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1056\/NEJM199608293350901","article-title":"Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group","volume":"335","author":"Abenhaim","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1124\/pr.111.005587_bib3","unstructured":"Adcirca [U.S. package insert]. Eli Lilly and Co., Indianapolis, IN."},{"key":"10.1124\/pr.111.005587_bib4","unstructured":"Actelion (2012) Actelion\u2019s macitentan meets primary endpoint in pivotal Phase III SERAPHIN outcome study in patients with pulmonary arterial hypertension 2012 Apr 30. Available at http:\/\/www.actelion.com\/en\/our-company\/news-and-events\/index.page?newsId=1607160."},{"key":"10.1124\/pr.111.005587_bib5","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.pupt.2005.09.006","article-title":"Sildenafil improves hemodynamic parameters in COPD\u2013an investigation of six patients","volume":"19","author":"Alp","year":"2006","journal-title":"Pulm Pharmacol Ther"},{"key":"10.1124\/pr.111.005587_bib6","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1164\/ajrccm.166.1.at1102","article-title":"ATS statement: guidelines for the six-minute walk test","volume":"166","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1124\/pr.111.005587_bib7","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/j.1755-5922.2011.00279.x","article-title":"ARIES-3: ambrisentan therapy in a diverse population of patients with pulmonary hypertension","volume":"30","author":"Badesch","year":"2012","journal-title":"Cardiovasc Ther"},{"key":"10.1124\/pr.111.005587_bib8","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.3899\/jrheum.081277","article-title":"Long-term survival among patients with scleroderma-associated pulmonary arterial hypertension treated with intravenous epoprostenol","volume":"36","author":"Badesch","year":"2009","journal-title":"J Rheumatol"},{"key":"10.1124\/pr.111.005587_bib9","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1378\/chest.09-1140","article-title":"Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry","volume":"137","author":"Badesch","year":"2010","journal-title":"Chest"},{"key":"10.1124\/pr.111.005587_bib10","doi-asserted-by":"crossref","first-page":"425","DOI":"10.7326\/0003-4819-132-6-200003210-00002","article-title":"Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial","volume":"132","author":"Badesch","year":"2000","journal-title":"Ann Intern Med"},{"key":"10.1124\/pr.111.005587_bib11","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1542\/peds.2005-0523","article-title":"Oral sildenafil in infants with persistent pulmonary hypertension of the newborn: a pilot randomized blinded study","volume":"117","author":"Baquero","year":"2006","journal-title":"Pediatrics"},{"key":"10.1124\/pr.111.005587_bib12","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1517\/14656566.8.1.95","article-title":"Sitaxsentan: a selective endothelin-A receptor antagonist, for the treatment of pulmonary arterial hypertension","volume":"8","author":"Barst","year":"2007","journal-title":"Expert Opin Pharmacother"},{"key":"10.1124\/pr.111.005587_bib13","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1183\/09031936.00056110","article-title":"Pulmonary arterial hypertension: a comparison between children and adults","volume":"37","author":"Barst","year":"2011","journal-title":"Eur Respir J"},{"key":"10.1124\/pr.111.005587_bib14","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1183\/09031936.06.00044406","article-title":"Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil","volume":"28","author":"Barst","year":"2006","journal-title":"Eur Respir J"},{"key":"10.1124\/pr.111.005587_bib15","doi-asserted-by":"crossref","first-page":"S78","DOI":"10.1016\/j.jacc.2009.04.017","article-title":"Updated evidence-based treatment algorithm in pulmonary arterial hypertension","volume":"54","author":"Barst","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1124\/pr.111.005587_bib16","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/S0009-9236(03)00005-5","article-title":"Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension","volume":"73","author":"Barst","year":"2003","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/pr.111.005587_bib17","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1161\/CIRCULATIONAHA.110.016667","article-title":"A randomized, double-blind, placebo-controlled, dose-ranging study of oral sildenafil citrate in treatment-naive children with pulmonary arterial hypertension","volume":"125","author":"Barst","year":"2012","journal-title":"Circulation"},{"key":"10.1124\/pr.111.005587_bib18","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1016\/j.jacc.2006.01.057","article-title":"Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan","volume":"47","author":"Barst","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"10.1124\/pr.111.005587_bib19","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1164\/rccm.200307-957OC","article-title":"Sitaxsentan therapy for pulmonary arterial hypertension","volume":"169","author":"Barst","year":"2004","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1124\/pr.111.005587_bib20","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1161\/01.CIR.99.9.1197","article-title":"Vasodilator therapy for primary pulmonary hypertension in children","volume":"99","author":"Barst","year":"1999","journal-title":"Circulation"},{"key":"10.1124\/pr.111.005587_bib21","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1016\/S0735-1097(03)00463-7","article-title":"Beraprost therapy for pulmonary arterial hypertension","volume":"41","author":"Barst","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"10.1124\/pr.111.005587_bib22","doi-asserted-by":"crossref","first-page":"40S","DOI":"10.1016\/j.jacc.2004.02.032","article-title":"Diagnosis and differential assessment of pulmonary arterial hypertension","volume":"43","author":"Barst","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"10.1124\/pr.111.005587_bib23","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1111\/j.1365-2141.2010.08097.x","article-title":"Exercise capacity and haemodynamics in patients with sickle cell disease with pulmonary hypertension treated with bosentan: results of the ASSET studies","volume":"149","author":"Barst","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1124\/pr.111.005587_bib24","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.healun.2010.11.009","article-title":"Tadalafil monotherapy and as add-on to background bosentan in patients with pulmonary arterial hypertension","volume":"30","author":"Barst","year":"2011","journal-title":"J Heart Lung Transplant"},{"key":"10.1124\/pr.111.005587_bib25","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1056\/NEJM199602013340504","article-title":"A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group","volume":"334","author":"Barst","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1124\/pr.111.005587_bib26","doi-asserted-by":"crossref","first-page":"e51","DOI":"10.1016\/j.thromres.2010.01.007","article-title":"Bosentan for chronic thromboembolic pulmonary hypertension: findings from a systematic review and meta-analysis","volume":"126","author":"Becattini","year":"2010","journal-title":"Thromb Res"},{"key":"10.1124\/pr.111.005587_bib27","doi-asserted-by":"crossref","first-page":"225","DOI":"10.2174\/157016109787455653","article-title":"Bosentan in pediatric patients with pulmonary arterial hypertension","volume":"7","author":"Beghetti","year":"2009","journal-title":"Curr Vasc Pharmacol"},{"key":"10.1124\/pr.111.005587_bib28","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1111\/j.1365-2125.2009.03532.x","article-title":"Pharmacokinetic and clinical profile of a novel formulation of bosentan in children with pulmonary arterial hypertension: the FUTURE-1 study","volume":"68","author":"Beghetti","year":"2009","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/pr.111.005587_bib29","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1203\/PDR.0b013e318179954c","article-title":"Safety experience with bosentan in 146 children 2\u201311 years old with pulmonary arterial hypertension: results from the European Postmarketing Surveillance program","volume":"64","author":"Beghetti","year":"2008","journal-title":"Pediatr Res"},{"key":"10.1124\/pr.111.005587_bib30","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1183\/09031936.02.00094302","article-title":"Aerosolized iloprost induces a mild but sustained inhibition of platelet aggregation","volume":"19","author":"Beghetti","year":"2002","journal-title":"Eur Respir J"},{"key":"10.1124\/pr.111.005587_bib31","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/j.healun.2011.08.011","article-title":"The Registry of the International Society for Heart and Lung Transplantation: Fourteenth Pediatric Lung and Heart-Lung Transplantation Report\u20132011","volume":"30","author":"Benden","year":"2011","journal-title":"J Heart Lung Transplant"},{"key":"10.1124\/pr.111.005587_bib32","doi-asserted-by":"crossref","first-page":"840A","DOI":"10.1378\/chest.10295","article-title":"Safety and efficacy of bosentan in combination with sildenafil in PAH patients who experience inadequate clinical response to monotherapy: the COMPASS-3 study (Abstract)","volume":"138","author":"Benza","year":"2010","journal-title":"Chest"},{"key":"10.1124\/pr.111.005587_bib33","doi-asserted-by":"crossref","DOI":"10.1378\/chest.11-1460","article-title":"An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from REVEAL","author":"Benza","year":"2012","journal-title":"Chest"},{"key":"10.1124\/pr.111.005587_bib34","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1161\/CIRCULATIONAHA.109.898122","article-title":"Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL)","volume":"122","author":"Benza","year":"2010","journal-title":"Circulation"},{"key":"10.1124\/pr.111.005587_bib35","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/j.healun.2011.08.019","article-title":"Long-term effects of inhaled treprostinil in patients with pulmonary arterial hypertension: The TReprostinil sodium Inhalation Used in the Management of Pulmonary arterial Hypertension (TRIUMPH) study open-label extension","volume":"30","author":"Benza","year":"2011","journal-title":"J Heart Lung Transplant"},{"key":"10.1124\/pr.111.005587_bib36","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1093\/rheumatology\/37.9.952","article-title":"Oral iloprost in Raynaud's phenomenon secondary to systemic sclerosis: a multicentre, placebo-controlled, dose-comparison study","volume":"37","author":"Black","year":"1998","journal-title":"Br J Rheumatol."},{"key":"10.1124\/pr.111.005587_bib37","first-page":"A3342","article-title":"Transitioning patients from inhaled iloprost to inhaled treprostinil sodium: an interim analysis (Abstract)","volume":"181","author":"Bourge","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1124\/pr.111.005587_bib38","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1177\/1753465808094762","article-title":"Therapeutic advances in pulmonary arterial hypertension","volume":"2","author":"Boutet","year":"2008","journal-title":"Ther Adv Respir Dis"},{"key":"10.1124\/pr.111.005587_bib39","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.leukres.2009.08.031","article-title":"Nilotinib: a second-generation tyrosine kinase inhibitor for chronic myeloid leukemia","volume":"34","author":"Breccia","year":"2010","journal-title":"Leuk Res"},{"key":"10.1124\/pr.111.005587_bib40","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s00228-007-0408-z","article-title":"Mutual pharmacokinetic interactions between steady-state bosentan and sildenafil","volume":"64","author":"Burgess","year":"2008","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/pr.111.005587_bib41","doi-asserted-by":"crossref","first-page":"25","DOI":"10.21693\/1933-088X-8.1.24","article-title":"Evaluating recent therapeutic trials in pulmonary arterial hypertension: raising the bar for clinical investigation","volume":"8","author":"Chakinala","year":"2009","journal-title":"Adv Pulm Hypertens"},{"key":"10.1124\/pr.111.005587_bib42","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/S0140-6736(01)06250-X","article-title":"Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study","volume":"358","author":"Channick","year":"2001","journal-title":"Lancet"},{"key":"10.1124\/pr.111.005587_bib43","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1164\/rccm.200810-1603OC","article-title":"Impact of the lung allocation score on lung transplantation for pulmonary arterial hypertension","volume":"180","author":"Chen","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1124\/pr.111.005587_bib44","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/j.healun.2011.08.004","article-title":"The Registry of the International Society for Heart and Lung Transplantation: Twenty-eighth Adult Lung and Heart-Lung Transplant Report\u20132011","volume":"30","author":"Christie","year":"2011","journal-title":"J Heart Lung Transplant"},{"key":"10.1124\/pr.111.005587_bib45","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1056\/NEJM199207093270202","article-title":"An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension","volume":"327","author":"Christman","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1124\/pr.111.005587_bib46","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1056\/NEJM200002173420704","article-title":"Low-dose nitric oxide therapy for persistent pulmonary hypertension of the newborn. Clinical Inhaled Nitric Oxide Research Group","volume":"342","author":"Clark","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1124\/pr.111.005587_bib47","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1165\/ajrcmb.26.2.4695","article-title":"Differential effects of stable prostacyclin analogs on smooth muscle proliferation and cyclic AMP generation in human pulmonary artery","volume":"26","author":"Clapp","year":"2002","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1124\/pr.111.005587_bib48","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/j.bbrc.2005.06.183","article-title":"High lung PDE5: a strong basis for treating pulmonary hypertension with PDE5 inhibitors","volume":"334","author":"Corbin","year":"2005","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1124\/pr.111.005587_bib49","doi-asserted-by":"crossref","first-page":"343","DOI":"10.7326\/0003-4819-115-5-343","article-title":"Survival in patients with primary pulmonary hypertension. Results from a national prospective registry","volume":"115","author":"D'Alonzo","year":"1991","journal-title":"Ann Intern Med"},{"key":"10.1124\/pr.111.005587_bib50","doi-asserted-by":"crossref","first-page":"259","DOI":"10.4103\/2045-8932.83448","article-title":"Hypoxic pulmonary hypertension in mice with constitutively active platelet-derived growth factor receptor-\u03b2","volume":"1","author":"Dahal","year":"2011","journal-title":"Pulm Circ"},{"key":"10.1124\/pr.111.005587_bib51","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1542\/peds.101.3.325","article-title":"Inhaled nitric oxide for the early treatment of persistent pulmonary hypertension of the term newborn: a randomized, double-masked, placebo-controlled, dose-response, multicenter study. The I-NO\/PPHN Study Group","volume":"101","author":"Davidson","year":"1998","journal-title":"Pediatrics"},{"key":"10.1124\/pr.111.005587_bib52","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1164\/ajrccm.165.3.2104059","article-title":"ET(A) and ET(B) receptors modulate the proliferation of human pulmonary artery smooth muscle cells","volume":"165","author":"Davie","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1124\/pr.111.005587_bib53","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1634\/theoncologist.12-12-1390","article-title":"Imatinib","volume":"12","author":"de Kogel","year":"2007","journal-title":"Oncologist"},{"key":"10.1124\/pr.111.005587_bib54","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/j.jtcvs.2011.08.055","article-title":"Outcome of patients with pulmonary arterial hypertension referred for lung transplantation: a 14-year single-center experience","volume":"143","author":"de Perrot","year":"2012","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1124\/pr.111.005587_bib55","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1378\/chest.11-0426","article-title":"Selective serotonin reuptake inhibitors and pulmonary arterial hypertension: a case-control study","volume":"141","author":"Dhalla","year":"2012","journal-title":"Chest"},{"key":"10.1124\/pr.111.005587_bib56","doi-asserted-by":"crossref","first-page":"3020","DOI":"10.1161\/CIRCULATIONAHA.108.769646","article-title":"Circulating endothelial progenitor cells in patients with Eisenmenger syndrome and idiopathic pulmonary arterial hypertension","volume":"117","author":"Diller","year":"2008","journal-title":"Circulation"},{"key":"10.1124\/pr.111.005587_bib57","doi-asserted-by":"crossref","first-page":"157","DOI":"10.3851\/IMP1506","article-title":"Mutual pharmacokinetic interactions between bosentan and lopinavir\/ritonavir in healthy participants","volume":"15","author":"Dingemanse","year":"2010","journal-title":"Antivir Ther"},{"key":"10.1124\/pr.111.005587_bib58","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1742-1241.2008.01811.x","article-title":"Guidelines for the prevention of central venous catheter-related blood stream infections with prostanoid therapy for pulmonary arterial hypertension","volume":"160","author":"Doran","year":"2008","journal-title":"Int J Clin Pract Suppl"},{"key":"10.1124\/pr.111.005587_bib59","first-page":"A6304","article-title":"Comparison of effects of imatinib and nilotinib in a rodent model of pulmonary arterial hypertension (Abstract)","volume":"181","author":"Duggan","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1124\/pr.111.005587_bib60","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1183\/09031936.00126010","article-title":"Terguride ameliorates monocrotaline-induced pulmonary hypertension in rats","volume":"37","author":"Dumitrascu","year":"2011","journal-title":"Eur Respir J"},{"key":"10.1124\/pr.111.005587_bib61","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/sj.ijir.3901490","article-title":"Phosphodiesterase type 5 inhibitors' extended duration of response as a variable in the treatment of erectile dysfunction","volume":"19","author":"Dunn","year":"2007","journal-title":"Int J Impot Res"},{"key":"10.1124\/pr.111.005587_bib62","first-page":"783","article-title":"The six-minute walk test","volume":"48","author":"Enright","year":"2003","journal-title":"Respir Care"},{"key":"10.1124\/pr.111.005587_bib63","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1183\/09031936.00112809","article-title":"Endothelial progenitors in pulmonary hypertension: new pathophysiology and therapeutic implications","volume":"35","author":"Fadini","year":"2010","journal-title":"Eur Respir J"},{"key":"10.1124\/pr.111.005587_bib64","unstructured":"Ergonex Pharma GmbH (2008) Ergonex Pharma initiates phase II clinical trial of Terguride in pulmonary arterial hypertension, 2008 Jan 29. Available at: http:\/\/www.ergonex.com\/attachments\/news\/26\/Media_Release_final_V2.pdf."},{"key":"10.1124\/pr.111.005587_bib65","first-page":"77","article-title":"Hepatotoxicity by bosentan in a patient with portopulmonary hypertension: a case-report and review of the literature","volume":"20","author":"Eriksson","year":"2011","journal-title":"J Gastrointestin Liver Dis"},{"key":"10.1124\/pr.111.005587_bib66","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1067\/mcp.2001.114667","article-title":"The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: a potential mechanism for hepatic adverse reactions","volume":"69","author":"Fattinger","year":"2001","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/pr.111.005587_bib67","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.amjcard.2010.11.030","article-title":"Comparison of inhaled nitric oxide versus oxygen on hemodynamics in patients with mitral stenosis and severe pulmonary hypertension after mitral valve surgery","volume":"107","author":"Fernandes","year":"2011","journal-title":"Am J Cardiol"},{"key":"10.1124\/pr.111.005587_bib68","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.1517\/14656566.2011.622269","article-title":"Inhaled treprostinil sodium for the treatment of pulmonary arterial hypertension","volume":"12","author":"Ferrantino","year":"2011","journal-title":"Expert Opin Pharmacother"},{"key":"10.1124\/pr.111.005587_bib69","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1007\/s00134-010-2065-4","article-title":"Intravenous sildenafil for postoperative pulmonary hypertension in children with congenital heart disease","volume":"37","author":"Fraisse","year":"2011","journal-title":"Intensive Care Med"},{"key":"10.1124\/pr.111.005587_bib70","doi-asserted-by":"crossref","first-page":"215","DOI":"10.2165\/11207340-000000000-00000","article-title":"Ambrisentan","volume":"11","author":"Frampton","year":"2011","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1124\/pr.111.005587_bib71","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1124\/pr.110.002907","article-title":"cGMP-dependent protein kinases and cGMP phosphodiesterases in nitric oxide and cGMP action","volume":"62","author":"Francis","year":"2010","journal-title":"Pharmacol Rev"},{"key":"10.1124\/pr.111.005587_bib72","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1378\/chest.112.3.714","article-title":"The effect of anticoagulant therapy in primary and anorectic drug-induced pulmonary hypertension","volume":"112","author":"Frank","year":"1997","journal-title":"Chest"},{"key":"10.1124\/pr.111.005587_bib73","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1378\/chest.10-0075","article-title":"The changing picture of patients with pulmonary arterial hypertension in the United States: how REVEAL differs from historic and non-US Contemporary Registries","volume":"139","author":"Frost","year":"2011","journal-title":"Chest"},{"key":"10.1124\/pr.111.005587_bib74","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1006\/bbrc.1994.1395","article-title":"Clearance of circulating endothelin-1 by ETB receptor in rats","volume":"199","author":"Fukuroda","year":"1994","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1124\/pr.111.005587_bib75","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1161\/01.CIR.70.4.580","article-title":"Primary pulmonary hypertension: natural history and the importance of thrombosis","volume":"70","author":"Fuster","year":"1984","journal-title":"Circulation"},{"key":"10.1124\/pr.111.005587_bib76","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1378\/chest.11-0404","article-title":"Race and sex differences in response to endothelin receptor antagonists for pulmonary arterial hypertension","volume":"141","author":"Gabler","year":"2012","journal-title":"Chest"},{"key":"10.1124\/pr.111.005587_bib77","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.jacc.2005.04.050","article-title":"Ambrisentan therapy for pulmonary arterial hypertension","volume":"46","author":"Gali\u00e9","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1124\/pr.111.005587_bib78","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1161\/CIRCULATIONAHA.106.630715","article-title":"Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study","volume":"114","author":"Gali\u00e9","year":"2006","journal-title":"Circulation"},{"key":"10.1124\/pr.111.005587_bib79","doi-asserted-by":"crossref","first-page":"2894","DOI":"10.1161\/CIRCULATIONAHA.108.839274","article-title":"Tadalafil therapy for pulmonary arterial hypertension","volume":"119","author":"Gali\u00e9","year":"2009","journal-title":"Circulation"},{"key":"10.1124\/pr.111.005587_bib80","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1056\/NEJMoa050010","article-title":"Sildenafil citrate therapy for pulmonary arterial hypertension","volume":"353","author":"Gali\u00e9","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1124\/pr.111.005587_bib81","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1183\/09031936.00194810","article-title":"Liver toxicity of sitaxentan in pulmonary arterial hypertension","volume":"37","author":"Gali\u00e9","year":"2011","journal-title":"Eur Respir J"},{"key":"10.1124\/pr.111.005587_bib82","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1093\/eurheartj\/ehp297","volume":"30","author":"Gali\u00e9","year":"2009","journal-title":"Eur Heart J"},{"key":"10.1124\/pr.111.005587_bib83","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1016\/S0735-1097(02)01786-2","article-title":"Effect of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial","volume":"39","author":"Gali\u00e9","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"10.1124\/pr.111.005587_bib84","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1183\/09059180.00003809","article-title":"The use of combination therapy in pulmonary arterial hypertension: new developments","volume":"18","author":"Gali\u00e9","year":"2009","journal-title":"Eur Respir Rev"},{"key":"10.1124\/pr.111.005587_bib85","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1161\/CIRCULATIONAHA.107.742510","article-title":"Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2","volume":"117","author":"Gali\u00e9","year":"2008","journal-title":"Circulation"},{"key":"10.1124\/pr.111.005587_bib86","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1016\/S0140-6736(08)60919-8","article-title":"Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial","volume":"371","author":"Gali\u00e9","year":"2008","journal-title":"Lancet"},{"key":"10.1124\/pr.111.005587_bib87","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/S0300-2896(08)75779-X","article-title":"[Experience with imatinib to treat pulmonary arterial hypertension]","volume":"44","author":"Garc\u00eda Hern\u00e1ndez","year":"2008","journal-title":"Arch Bronconeumol"},{"key":"10.1124\/pr.111.005587_bib88","doi-asserted-by":"crossref","first-page":"635","DOI":"10.2165\/11317820-000000000-00000","article-title":"Cost-utility of treatments for pulmonary arterial hypertension: a Markov state-transition decision analysis model","volume":"29","author":"Garin","year":"2009","journal-title":"Clin Drug Investig"},{"key":"10.1124\/pr.111.005587_bib89","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1183\/09031936.00182909","article-title":"Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: a phase II study","volume":"36","author":"Ghofrani","year":"2010","journal-title":"Eur Respir J"},{"key":"10.1124\/pr.111.005587_bib90","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1164\/rccm.201001-0123OC","article-title":"Imatinib in pulmonary arterial hypertension in patients with inadequate response to established therapy","volume":"182","author":"Ghofrani","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1124\/pr.111.005587_bib91","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1056\/NEJMc051946","article-title":"Imatinib for the treatment of pulmonary arterial hypertension","volume":"353","author":"Ghofrani","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1124\/pr.111.005587_bib92","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1056\/NEJM199306173282402","article-title":"Expression of endothelin-1 in the lungs of patients with pulmonary hypertension","volume":"328","author":"Giaid","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1124\/pr.111.005587_bib93","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1056\/NEJM199507273330403","article-title":"Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension","volume":"333","author":"Giaid","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1124\/pr.111.005587_bib94","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/j.healun.2011.04.009","article-title":"Lung transplantation in children with idiopathic pulmonary arterial hypertension: an 18-year experience","volume":"30","author":"Goldstein","year":"2011","journal-title":"J Heart Lung Transplant"},{"key":"10.1124\/pr.111.005587_bib95","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.jacc.2010.11.020","article-title":"Compelling evidence of long-term outcomes in pulmonary arterial hypertension? A clinical perspective","volume":"57","author":"Gomberg-Maitland","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1124\/pr.111.005587_bib96","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1164\/rccm.200505-766OC","article-title":"Transition from intravenous epoprostenol to intravenous treprostinil in pulmonary hypertension","volume":"172","author":"Gomberg-Maitland","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1124\/pr.111.005587_bib97","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1111\/j.1368-5031.2006.00904.x","article-title":"Sildenafil citrate use and the incidence of nonarteritic anterior ischemic optic neuropathy","volume":"60","author":"Gorkin","year":"2006","journal-title":"Int J Clin Pract"},{"key":"10.1124\/pr.111.005587_bib98","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1111\/j.1365-2125.2011.04034.x","article-title":"Anti-platelet therapy: phosphodiesterase inhibitors","volume":"72","author":"Gresele","year":"2011","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/pr.111.005587_bib99","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1183\/09031936.00039808","article-title":"First acute haemodynamic study of soluble guanylate cyclase stimulator riociguat in pulmonary hypertension","volume":"33","author":"Grimminger","year":"2009","journal-title":"Eur Respir J"},{"key":"10.1124\/pr.111.005587_bib100","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1177\/0091270009341182","article-title":"Acute hemodynamic effects of single-dose sildenafil when added to established bosentan therapy in patients with pulmonary arterial hypertension: results of the COMPASS-1 study","volume":"49","author":"Gruenig","year":"2009","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/pr.111.005587_bib101","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1161\/CIRCULATIONAHA.104.524926","article-title":"Serotonin transporter inhibition prevents and reverses monocrotaline-induced pulmonary hypertension in rats","volume":"111","author":"Guignabert","year":"2005","journal-title":"Circulation"},{"key":"10.1124\/pr.111.005587_bib102","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1016\/j.jacc.2009.04.006","article-title":"Inflammation, growth factors, and pulmonary vascular remodeling","volume":"54","author":"Hassoun","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1124\/pr.111.005587_bib103","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0002-9343(99)80156-9","article-title":"Increased plasma serotonin in primary pulmonary hypertension","volume":"99","author":"Herv\u00e9","year":"1995","journal-title":"Am J Med"},{"key":"10.1124\/pr.111.005587_bib104","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1136\/hrt.80.2.151","article-title":"Long-term intravenous prostaglandin (epoprostenol or iloprost) for treatment of severe pulmonary hypertension","volume":"80","author":"Higenbottam","year":"1998","journal-title":"Heart"},{"key":"10.1124\/pr.111.005587_bib105","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.healun.2009.09.005","article-title":"Exercise improvement and plasma biomarker changes with intravenous treprostinil therapy for pulmonary arterial hypertension: a placebo-controlled trial","volume":"29","author":"Hiremath","year":"2010","journal-title":"J Heart Lung Transplant"},{"key":"10.1124\/pr.111.005587_bib106","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1183\/09031936.00053510","article-title":"Long-term efficacy of bosentan in treatment of pulmonary arterial hypertension in children","volume":"38","author":"Hislop","year":"2011","journal-title":"Eur Respir J"},{"key":"10.1124\/pr.111.005587_bib107","unstructured":"Hoeper M, Barst RJ, Gali\u00e9 N, Hassoun P, Morrell N, Peacock A, Simonneau G, Tapson V, Torres F, Lu K, Quinn D, and Ghofrani HA (2011) Imatinib in pulmonary arterial hypertension, a randomized, efficacy study (IMPRES) (Abstract no. 413), in Annual Congress of the European Respiratory Society; 2011 Sep 25; Amsterdam, The Netherlands. p 50S. European Respiratory Society, Sheffield, UK."},{"key":"10.1124\/pr.111.005587_bib108","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1183\/09031936.05.00075305","article-title":"Goal-oriented treatment and combination therapy for pulmonary arterial hypertension","volume":"26","author":"Hoeper","year":"2005","journal-title":"Eur Respir J"},{"key":"10.1124\/pr.111.005587_bib109","doi-asserted-by":"crossref","first-page":"48S","DOI":"10.1016\/j.jacc.2004.02.010","article-title":"End points and clinical trial designs in pulmonary arterial hypertension: clinical and regulatory perspectives","volume":"43","author":"Hoeper","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"10.1124\/pr.111.005587_bib110","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1183\/09031936.04.00028404","article-title":"Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2","volume":"24","author":"Humbert","year":"2004","journal-title":"Eur Respir J"},{"key":"10.1124\/pr.111.005587_bib111","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1164\/rccm.200510-1668OC","article-title":"Pulmonary arterial hypertension in France: results from a national registry","volume":"173","author":"Humbert","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1124\/pr.111.005587_bib112","doi-asserted-by":"crossref","first-page":"3106","DOI":"10.1161\/01.CIR.0000134595.80170.62","article-title":"Inhaled nitric oxide: a selective pulmonary vasodilator: current uses and therapeutic potential","volume":"109","author":"Ichinose","year":"2004","journal-title":"Circulation"},{"key":"10.1124\/pr.111.005587_bib113","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1124\/jpet.108.142976","article-title":"Pharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonist","volume":"327","author":"Iglarz","year":"2008","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/pr.111.005587_bib114","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1086\/605320","article-title":"Closed-hub systems with protected connections and the reduction of risk of catheter-related bloodstream infection in pediatric patients receiving intravenous prostanoid therapy for pulmonary hypertension","volume":"30","author":"Ivy","year":"2009","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1124\/pr.111.005587_bib115","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.amjcard.2006.09.119","article-title":"Transition of stable pediatric patients with pulmonary arterial hypertension from intravenous epoprostenol to intravenous treprostinil","volume":"99","author":"Ivy","year":"2007","journal-title":"Am J Cardiol"},{"key":"10.1124\/pr.111.005587_bib116","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jacc.2007.09.031","article-title":"Short- and long-term effects of inhaled iloprost therapy in children with pulmonary arterial hypertension","volume":"51","author":"Ivy","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1124\/pr.111.005587_bib117","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1016\/j.amjcard.2010.06.064","article-title":"Long-term outcomes in children with pulmonary arterial hypertension treated with bosentan in real-world clinical settings","volume":"106","author":"Ivy","year":"2010","journal-title":"Am J Cardiol"},{"key":"10.1124\/pr.111.005587_bib118","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1016\/j.jacc.2008.08.059","article-title":"Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFiT (Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension), a randomized, placebo-controlled trial","volume":"52","author":"Ja\u00efs","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1124\/pr.111.005587_bib119","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1097\/00000441-199207000-00005","article-title":"Cicletanine blunts the pulmonary pressor response to acute hypoxia in rats","volume":"304","author":"Jin","year":"1992","journal-title":"Am J Med Sci"},{"key":"10.1124\/pr.111.005587_bib120","doi-asserted-by":"crossref","first-page":"276","DOI":"10.3899\/jrheum.110765","article-title":"Warfarin in systemic sclerosis-associated and idiopathic pulmonary arterial hypertension. A Bayesian approach to evaluating treatment for uncommon disease","volume":"39","author":"Johnson","year":"2012","journal-title":"J Rheumatol"},{"key":"10.1124\/pr.111.005587_bib121","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1183\/09031936.06.00015206","article-title":"Anticoagulation in pulmonary arterial hypertension: a qualitative systematic review","volume":"28","author":"Johnson","year":"2006","journal-title":"Eur Respir J"},{"key":"10.1124\/pr.111.005587_bib122","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/S0026-895X(25)10547-6","article-title":"Activation of thromboxane and prostacyclin receptors elicits opposing effects on vascular smooth muscle cell growth and mitogen-activated protein kinase signaling cascades","volume":"48","author":"Jones","year":"1995","journal-title":"Mol Pharmacol"},{"key":"10.1124\/pr.111.005587_bib123","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1097\/00005344-200106000-00009","article-title":"Cicletanine stimulates nitric oxide release and scavenges superoxide in endothelial cells","volume":"37","author":"Kalinowski","year":"2001","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1124\/pr.111.005587_bib124","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1086\/529552","article-title":"Bloodstream infections in patients given treatment with intravenous prostanoids","volume":"29","author":"Kallen","year":"2008","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1124\/pr.111.005587_bib125","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1378\/chest.10-1293","article-title":"Integration of clinical and hemodynamic parameters in the prediction of long-term survival in patients with pulmonary arterial hypertension","volume":"139","author":"Kane","year":"2011","journal-title":"Chest"},{"key":"10.1124\/pr.111.005587_bib126","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.pupt.2006.01.001","article-title":"Selective serotonin reuptake inhibitor use and outcomes in pulmonary arterial hypertension","volume":"19","author":"Kawut","year":"2006","journal-title":"Pulm Pharmacol Ther"},{"key":"10.1124\/pr.111.005587_bib127","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1146\/annurev.pharmtox.41.1.851","article-title":"Endothelin system: the double-edged sword in health and disease","volume":"41","author":"Kedzierski","year":"2001","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1124\/pr.111.005587_bib128","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1124\/jpet.111.187906","article-title":"Antiserotonergic properties of terguride in blood vessels, platelets and valvular interstitial cells","volume":"340","author":"Kekewska","year":"2012","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/pr.111.005587_bib129","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.healun.2011.11.002","article-title":"Usefulness of first-line combination therapy with epoprostenol and bosentan in pulmonary arterial hypertension: an observational study","volume":"31","author":"Kemp","year":"2012","journal-title":"J Heart Lung Transplant"},{"key":"10.1124\/pr.111.005587_bib130","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1161\/01.CIR.91.7.2028","article-title":"Blade balloon atrial septostomy in patients with severe primary pulmonary hypertension","volume":"91","author":"Kerstein","year":"1995","journal-title":"Circulation"},{"key":"10.1124\/pr.111.005587_bib131","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1161\/CIRCULATIONAHA.108.779751","article-title":"Combined tyrosine and serine\/threonine kinase inhibition by sorafenib prevents progression of experimental pulmonary hypertension and myocardial remodeling","volume":"118","author":"Klein","year":"2008","journal-title":"Circulation"},{"key":"10.1124\/pr.111.005587_bib132","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1016\/j.leukres.2008.02.023","article-title":"Improvement of cardiac function, mitral regurgitation and pulmonary hypertension in a patient with chronic eosinophilic leukemia (CEL) after low dose imatinib therapy","volume":"32","author":"Krauth","year":"2008","journal-title":"Leuk Res"},{"key":"10.1124\/pr.111.005587_bib133","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1124\/jpet.107.124248","article-title":"2-[4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy]-N-(methylsulfonyl)acetamide (NS-304), an orally available and long-acting prostacyclin receptor agonist prodrug","volume":"322","author":"Kuwano","year":"2007","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/pr.111.005587_bib134","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1097\/00005344-200408000-00010","article-title":"Pharmacokinetics and steady-state bioequivalence of treprostinil sodium (Remodulin) administered by the intravenous and subcutaneous route to normal volunteers","volume":"44","author":"Laliberte","year":"2004","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1124\/pr.111.005587_bib135","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1136\/hrt.2006.096412","article-title":"Epoprostenol treatment in children with severe pulmonary hypertension","volume":"93","author":"Lammers","year":"2007","journal-title":"Heart"},{"key":"10.1124\/pr.111.005587_bib136","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.ccm.2010.10.006","article-title":"Pregnancy and pulmonary hypertension","volume":"32","author":"Lane","year":"2011","journal-title":"Clin Chest Med"},{"key":"10.1124\/pr.111.005587_bib137","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1378\/chest.129.6.1636","article-title":"Efficacy of long-term subcutaneous treprostinil sodium therapy in pulmonary hypertension","volume":"129","author":"Lang","year":"2006","journal-title":"Chest"},{"key":"10.1124\/pr.111.005587_bib138","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1182\/blood-2011-06-358374","article-title":"Serotonin 5-HT2B receptors are required for bone-marrow contribution to pulmonary arterial hypertension","volume":"119","author":"Launay","year":"2012","journal-title":"Blood"},{"key":"10.1124\/pr.111.005587_bib139","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1038\/nm764","article-title":"Function of the serotonin 5-hydroxytryptamine 2B receptor in pulmonary hypertension","volume":"8","author":"Launay","year":"2002","journal-title":"Nat Med"},{"key":"10.1124\/pr.111.005587_bib140","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.pupt.2007.01.003","article-title":"Plasma serotonin levels are normal in pulmonary arterial hypertension","volume":"21","author":"Lederer","year":"2008","journal-title":"Pulm Pharmacol Ther"},{"key":"10.1124\/pr.111.005587_bib141","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1183\/09031936.00091610","article-title":"Sitaxentan-related acute liver failure in a patient with pulmonary arterial hypertension","volume":"37","author":"Lee","year":"2011","journal-title":"Eur Respir J"},{"key":"10.1124\/pr.111.005587_bib142","unstructured":"Letairis [U.S. package insert]. (2011) Gilead Sciences, Inc., Foster City, CA."},{"key":"10.1124\/pr.111.005587_bib143","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1056\/NEJM199508103330607","article-title":"Endothelins","volume":"333","author":"Levin","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1124\/pr.111.005587_bib144","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.jpeds.2010.09.025","article-title":"Add-on therapy with subcutaneous treprostinil for refractory pediatric pulmonary hypertension","volume":"158","author":"Levy","year":"2011","journal-title":"J Pediatr"},{"key":"10.1124\/pr.111.005587_bib145","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1182\/blood-2010-09-306167","article-title":"Hospitalization for pain in patients with sickle cell disease treated with sildenafil for elevated TRV and low exercise capacity","volume":"118","author":"Machado","year":"2011","journal-title":"Blood"},{"key":"10.1124\/pr.111.005587_bib146","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1161\/01.CIR.0000127375.56172.92","article-title":"Overexpression of the 5-hydroxytryptamin transporter gene: effect on pulmonary hemodynamics and hypoxia-induced pulmonary hypertension","volume":"109","author":"MacLean","year":"2004","journal-title":"Circulation"},{"key":"10.1124\/pr.111.005587_bib147","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/sj.bjp.0703570","article-title":"5-hydroxytryptamine and the pulmonary circulation: receptors, transporters and relevance to pulmonary arterial hypertension","volume":"131","author":"MacLean","year":"2000","journal-title":"Br J Pharmacol"},{"key":"10.1124\/pr.111.005587_bib148","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1007\/s00134-003-2122-3","article-title":"Inhaled nitric oxide therapy in neonates and children: reaching a European consensus","volume":"30","author":"Macrae","year":"2004","journal-title":"Intensive Care Med"},{"key":"10.1124\/pr.111.005587_bib149","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1136\/hrt.2005.072314","article-title":"Response to bosentan in children with pulmonary hypertension","volume":"92","author":"Maiya","year":"2006","journal-title":"Heart"},{"key":"10.1124\/pr.111.005587_bib150","unstructured":"Massachusetts Executive Office of Health and Human Services (2011) Table 43: pulmonary arterial hypertension agents. Available at https:\/\/masshealthdruglist.ehs.state.ma.us\/MHDL\/pubtheradetail.do?id=43."},{"key":"10.1124\/pr.111.005587_bib151","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1161\/CIRCHEARTFAILURE.111.963314","article-title":"Inhaled NO and sildenafil combination in cardiac surgery patients with out-of-proportion pulmonary hypertension: acute effects on postoperative gas exchange and hemodynamics","volume":"5","author":"Matamis","year":"2012","journal-title":"Circ Heart Fail"},{"key":"10.1124\/pr.111.005587_bib152","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1016\/j.healun.2010.06.013","article-title":"Subcutaneous treprostinil in pulmonary arterial hypertension: Practical considerations","volume":"29","author":"Mathier","year":"2010","journal-title":"J Heart Lung Transplant"},{"key":"10.1124\/pr.111.005587_bib153","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1378\/chest.08-1028","article-title":"Ambrisentan therapy in patients with pulmonary arterial hypertension who discontinued bosentan or sitaxsentan due to liver function test abnormalities","volume":"135","author":"McGoon","year":"2009","journal-title":"Chest"},{"key":"10.1124\/pr.111.005587_bib154","doi-asserted-by":"crossref","first-page":"191","DOI":"10.4065\/84.2.191","article-title":"Pulmonary hypertension: diagnosis and management","volume":"84","author":"McGoon","year":"2009","journal-title":"Mayo Clin Proc"},{"key":"10.1124\/pr.111.005587_bib155","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1016\/j.jacc.2009.01.004","volume":"53","author":"McLaughlin","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1124\/pr.111.005587_bib156","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/j.jacc.2010.01.027","article-title":"Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial","volume":"55","author":"McLaughlin","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1124\/pr.111.005587_bib157","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.cpcardiol.2011.08.002","article-title":"Pulmonary arterial hypertension","volume":"36","author":"McLaughlin","year":"2011","journal-title":"Curr Probl Cardiol"},{"key":"10.1124\/pr.111.005587_bib158","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1097\/00005344-200302000-00019","article-title":"Efficacy and safety of treprostinil: an epoprostenol analogue for primary pulmonary hypertension","volume":"41","author":"McLaughlin","year":"2003","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1124\/pr.111.005587_bib159","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1161\/01.CIR.0000029100.82385.58","article-title":"Survival in primary pulmonary hypertension: the impact of epoprostenol therapy","volume":"106","author":"McLaughlin","year":"2002","journal-title":"Circulation"},{"key":"10.1124\/pr.111.005587_bib160","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1016\/j.amjcard.2009.12.075","article-title":"Effectiveness of transition from intravenous epoprostenol to oral\/inhaled targeted pulmonary arterial hypertension therapy in pediatric idiopathic and familial pulmonary arterial hypertension","volume":"105","author":"Melnick","year":"2010","journal-title":"Am J Cardiol"},{"key":"10.1124\/pr.111.005587_bib161","first-page":"612","article-title":"Deleterious effect of nifedipine on pulmonary gas exchange in chronic obstructive pulmonary disease","volume":"130","author":"Melot","year":"1984","journal-title":"Am Rev Respir Dis"},{"key":"10.1124\/pr.111.005587_bib162","doi-asserted-by":"crossref","first-page":"39S","DOI":"10.1378\/chest.10-0087","article-title":"Pulmonary hypertension in COPD: epidemiology, significance, and management: pulmonary vascular disease: the global perspective","volume":"137","author":"Minai","year":"2010","journal-title":"Chest"},{"key":"10.1124\/pr.111.005587_bib163","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1002\/cmdc.200900014","article-title":"Discovery of riociguat (BAY 63\u20132521): a potent, oral stimulator of soluble guanylate cyclase for the treatment of pulmonary hypertension","volume":"4","author":"Mittendorf","year":"2009","journal-title":"ChemMedChem"},{"key":"10.1124\/pr.111.005587_bib164","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1164\/ajrccm.161.2.9906015","article-title":"Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing","volume":"161","author":"Miyamoto","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1124\/pr.111.005587_bib165","article-title":"Inhaled iloprost for the control of acute pulmonary hypertension in children: A systematic review","author":"Mulligan","year":"2011","journal-title":"Pediatr Crit Care Med"},{"key":"10.1124\/pr.111.005587_bib166","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1161\/01.CIR.0000079161.56080.22","article-title":"Hybrid cell-gene therapy for pulmonary hypertension based on phagocytosing action of endothelial progenitor cells","volume":"108","author":"Nagaya","year":"2003","journal-title":"Circulation"},{"key":"10.1124\/pr.111.005587_bib167","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.jacc.2008.08.069","article-title":"Sildenafil stops progressive chamber, cellular, and molecular remodeling and improves calcium handling and function in hearts with pre-existing advanced hypertrophy caused by pressure overload","volume":"53","author":"Nagayama","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1124\/pr.111.005587_bib168","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1146\/annurev.pharmtox.43.100901.140226","article-title":"Nitric oxide-releasing drugs","volume":"43","author":"Napoli","year":"2003","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1124\/pr.111.005587_bib169","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1152\/physrev.1999.79.4.1193","article-title":"Prostanoid receptors: structures, properties, and functions","volume":"79","author":"Narumiya","year":"1999","journal-title":"Physiol Rev"},{"key":"10.1124\/pr.111.005587_bib170","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1056\/NEJM199702273360901","article-title":"Inhaled nitric oxide in full-term and nearly full-term infants with hypoxic respiratory failure. The Neonatal Inhaled Nitric Oxide Study Group","volume":"336","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1124\/pr.111.005587_bib171","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1124\/jpet.102.039875","article-title":"Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. II. Agonist and antagonist properties at subtypes of dopamine D(2)-like receptor and alpha(1)\/alpha(2)-adrenoceptor","volume":"303","author":"Newman-Tancredi","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/pr.111.005587_bib172","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1124\/jpet.102.039883","article-title":"Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. III. Agonist and antagonist properties at serotonin, 5-HT(1) and 5-HT(2), receptor subtypes","volume":"303","author":"Newman-Tancredi","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/pr.111.005587_bib173","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1016\/S0140-6736(97)24019-5","article-title":"Orally active prostacyclin analogue in primary pulmonary hypertension","volume":"349","author":"Okano","year":"1997","journal-title":"Lancet"},{"key":"10.1124\/pr.111.005587_bib174","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.pharmthera.2004.01.003","article-title":"Prostacyclin and its analogues in the treatment of pulmonary hypertension","volume":"102","author":"Olschewski","year":"2004","journal-title":"Pharmacol Ther"},{"key":"10.1124\/pr.111.005587_bib175","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1056\/NEJMoa020204","article-title":"Inhaled iloprost for severe pulmonary hypertension","volume":"347","author":"Olschewski","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1124\/pr.111.005587_bib176","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1093\/eurheartj\/ehn234","article-title":"Inhibition of endothelin receptors in the treatment of pulmonary arterial hypertension: does selectivity matter?","volume":"29","author":"Opitz","year":"2008","journal-title":"Eur Heart J"},{"key":"10.1124\/pr.111.005587_bib177","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1016\/j.jacc.2009.07.033","article-title":"Long-term ambrisentan therapy for the treatment of pulmonary arterial hypertension","volume":"54","author":"Oudiz","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1124\/pr.111.005587_bib178","doi-asserted-by":"crossref","first-page":"905A","DOI":"10.1378\/chest.1113577","article-title":"ATHENA-1: Hemodynamic improvements following the addition of ambrisentan to background PDE5i therapy in patients with pulmonary arterial hypertension (Abstract)","volume":"140","author":"Oudiz","year":"2011","journal-title":"Chest"},{"key":"10.1124\/pr.111.005587_bib179","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1183\/09031936.00054407","article-title":"Possible role of imatinib in clinical pulmonary veno-occlusive disease","volume":"32","author":"Overbeek","year":"2008","journal-title":"Eur Respir J"},{"key":"10.1124\/pr.111.005587_bib180","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1183\/09031936.01.17406470","article-title":"Oxygen desaturation on the six-minute walk test and mortality in untreated primary pulmonary hypertension","volume":"17","author":"Paciocco","year":"2001","journal-title":"Eur Respir J"},{"key":"10.1124\/pr.111.005587_bib181","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1136\/hrt.52.1.106","article-title":"Detrimental effects of verapamil in patients with primary pulmonary hypertension","volume":"52","author":"Packer","year":"1984","journal-title":"Br Heart J"},{"key":"10.1124\/pr.111.005587_bib182","doi-asserted-by":"crossref","first-page":"152","DOI":"10.7326\/0003-4819-145-2-200607180-00020","article-title":"Imatinib mesylate in the treatment of refractory idiopathic pulmonary arterial hypertension","volume":"145","author":"Patterson","year":"2006","journal-title":"Ann Intern Med"},{"key":"10.1124\/pr.111.005587_bib183","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1183\/09031936.00092306","article-title":"An epidemiological study of pulmonary arterial hypertension","volume":"30","author":"Peacock","year":"2007","journal-title":"Eur Respir J"},{"key":"10.1124\/pr.111.005587_bib184","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1164\/rccm.200707-1037OC","article-title":"Platelet-derived growth factor expression and function in idiopathic pulmonary arterial hypertension","volume":"178","author":"Perros","year":"2008","journal-title":"Am J Resp Crit Care Med"},{"key":"10.1124\/pr.111.005587_bib185","unstructured":"Pfizer Direct Healthcare Professional Communication (2011) Increased risk of mortality in paediatric patients with pulmonary arterial hypertension with the use of higher than recommended doses of Revatio (sildenafil citrate). Pfizer, Inc., New York, NY. Available at http:\/\/www.imb.ie\/images\/uploaded\/documents\/Pfizer%20Revatio%20DHPC%2004.09.11.pdf."},{"key":"10.1124\/pr.111.005587_bib186","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1124\/jpet.109.165001","article-title":"PRX-08066, a novel 5-hydroxytryptamine receptor 2B antagonist, reduces monocrotaline-induced pulmonary arterial hypertension and right ventricular hypertrophy in rats","volume":"334","author":"Porvasnik","year":"2010","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/pr.111.005587_bib187","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1183\/09031936.00068009","article-title":"Intravenous iloprost for pulmonary arterial hypertension: still waiting for evidence","volume":"34","author":"Provencher","year":"2009","journal-title":"Eur Respir J"},{"key":"10.1124\/pr.111.005587_bib188","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1146\/annurev.pathol.2.010506.092033","article-title":"Pathobiology of pulmonary hypertension","volume":"2","author":"Rabinovitch","year":"2007","journal-title":"Annu Rev Pathol"},{"key":"10.1124\/pr.111.005587_bib189","unstructured":"Red Book 2010, 114th ed. PDR Network, LLC, Montvale, NJ."},{"key":"10.1124\/pr.111.005587_bib190","unstructured":"Revatio [U.S. package insert]. (2005) Pfizer, Inc., New York, NY."},{"key":"10.1124\/pr.111.005587_bib191","unstructured":"Revatio [Summary of Product Characteristics] (2012). European Medicines Agency. London, UK. Available at: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000638\/WC500055840.pdf."},{"key":"10.1124\/pr.111.005587_bib192","doi-asserted-by":"crossref","first-page":"216","DOI":"10.7326\/0003-4819-107-2-216","article-title":"Primary pulmonary hypertension. A national prospective study","volume":"107","author":"Rich","year":"1987","journal-title":"Ann Intern Med"},{"key":"10.1124\/pr.111.005587_bib193","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1378\/chest.11-0245","article-title":"The effect of diluent pH on bloodstream infection rates in patients receiving IV treprostinil for pulmonary arterial hypertension","volume":"141","author":"Rich","year":"2012","journal-title":"Chest"},{"key":"10.1124\/pr.111.005587_bib194","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1021\/jm960274q","article-title":"Discovery and optimization of a novel class of orally active nonpeptidic endothelin-A receptor antagonists","volume":"39","author":"Riechers","year":"1996","journal-title":"J Med Chem."},{"key":"10.1124\/pr.111.005587_bib195","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.jacc.2005.01.066","article-title":"Effects of long-term bosentan in children with pulmonary arterial hypertension","volume":"46","author":"Rosenzweig","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1124\/pr.111.005587_bib196","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/S0002-9149(99)00416-6","article-title":"Atrial septostomy as a bridge to lung transplantation in patients with severe pulmonary hypertension","volume":"84","author":"Rothman","year":"1999","journal-title":"Am J Cardiol"},{"key":"10.1124\/pr.111.005587_bib197","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1378\/chest.06-2118","article-title":"Transition from IV epoprostenol to subcutaneous treprostinil in pulmonary arterial hypertension: a controlled trial","volume":"132","author":"Rubenfire","year":"2007","journal-title":"Chest"},{"key":"10.1124\/pr.111.005587_bib198","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1378\/chest.120.5.1562","article-title":"Big endothelin-1 and endothelin-1 plasma levels are correlated with the severity of primary pulmonary hypertension","volume":"120","author":"Rubens","year":"2001","journal-title":"Chest"},{"key":"10.1124\/pr.111.005587_bib199","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMoa012212","article-title":"Bosentan therapy for pulmonary arterial hypertension","volume":"346","author":"Rubin","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1124\/pr.111.005587_bib200","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1378\/chest.10-0969","article-title":"Long-term treatment with sildenafil citrate in pulmonary arterial hypertension: the SUPER-2 study","volume":"140","author":"Rubin","year":"2011","journal-title":"Chest"},{"key":"10.1124\/pr.111.005587_bib201","doi-asserted-by":"crossref","first-page":"1044A","DOI":"10.1378\/chest.1212098","article-title":"FREEDOM-M: Efficacy and safety of oral treprostinil diethanolamine as monotherapy in patients with pulmonary arterial hypertension (Abstract)","volume":"140","author":"Rubin","year":"2011","journal-title":"Chest"},{"key":"10.1124\/pr.111.005587_bib202","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/S0002-9149(96)90408-7","article-title":"Short-term hemodynamic effect of a new oral PGI2 analogue, beraprost, in primary and secondary pulmonary hypertension","volume":"78","author":"Saji","year":"1996","journal-title":"Am J Cardiol"},{"key":"10.1124\/pr.111.005587_bib203","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1183\/09031936.00072210","article-title":"Effect of atrial septostomy on the survival of patients with severe pulmonary arterial hypertension","volume":"38","author":"Sandoval","year":"2011","journal-title":"Eur Respir J"},{"key":"10.1124\/pr.111.005587_bib204","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.pupt.2011.10.002","article-title":"Safety and efficacy of sitaxsentan 50 and 100 mg in patients with pulmonary arterial hypertension","volume":"25","author":"Sandoval","year":"2012","journal-title":"Pulm Pharmacol Ther"},{"key":"10.1124\/pr.111.005587_bib205","doi-asserted-by":"crossref","first-page":"2811","DOI":"10.1172\/JCI24838","article-title":"Reversal of experimental pulmonary hypertension by PDGF inhibition","volume":"115","author":"Schermuly","year":"2005","journal-title":"J Clin Invest."},{"key":"10.1124\/pr.111.005587_bib206","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1183\/09031936.00114407","article-title":"Expression and function of soluble guanylate cyclase in pulmonary arterial hypertension","volume":"32","author":"Schermuly","year":"2008","journal-title":"Eur Respir J"},{"key":"10.1124\/pr.111.005587_bib207","first-page":"1108","article-title":"Inhaled nitric oxide versus intravenous vasodilators in severe pulmonary hypertension after cardiac surgery","volume":"89","author":"Schmid","year":"1999","journal-title":"Anesth Analg"},{"key":"10.1124\/pr.111.005587_bib208","first-page":"63","article-title":"Roles of vasodilatory prostaglandins in mitogenesis of vascular smooth muscle cells","volume":"48","author":"Schr\u00f6r","year":"1997","journal-title":"Agents Actions Suppl"},{"key":"10.1124\/pr.111.005587_bib209","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1378\/chest.08-2823","article-title":"Selective serotonin reuptake inhibitors and the incidence and outcome of pulmonary hypertension","volume":"136","author":"Shah","year":"2009","journal-title":"Chest"},{"key":"10.1124\/pr.111.005587_bib210","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/S0735-1097(97)00187-3","article-title":"Primary pulmonary hypertension: improved long-term effects and survival with continuous intravenous epoprostenol infusion","volume":"30","author":"Shapiro","year":"1997","journal-title":"J Am Coll Cardiol"},{"key":"10.1124\/pr.111.005587_bib211","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1007\/s00228-011-1043-2","article-title":"Macitentan: entry-into-humans study with a new endothelin receptor antagonist","volume":"67","author":"Sidharta","year":"2011","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/pr.111.005587_bib212","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1164\/ajrccm.165.6.2106079","article-title":"Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial","volume":"165","author":"Simonneau","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1124\/pr.111.005587_bib213","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.1016\/j.jacc.2009.04.012","article-title":"Updated clinical classification of pulmonary hypertension","volume":"54","author":"Simonneau","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1124\/pr.111.005587_bib214","doi-asserted-by":"crossref","first-page":"521","DOI":"10.7326\/0003-4819-149-8-200810210-00004","article-title":"Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial","volume":"149","author":"Simonneau","year":"2008","journal-title":"Ann Intern Med"},{"key":"10.1124\/pr.111.005587_bib215","doi-asserted-by":"crossref","DOI":"10.1183\/09031936.00137511","article-title":"Selexipag, on oral, selective IP receptor agonist for the treatment of pulmonary arterial hypertension","author":"Simonneau","year":"2012","journal-title":"Eur Respir J"},{"key":"10.1124\/pr.111.005587_bib216","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1164\/rccm.200404-445OC","article-title":"Bosentan for the treatment of human immunodeficiency virus-associated pulmonary arterial hypertension","volume":"170","author":"Sitbon","year":"2004","journal-title":"Am J Resp Crit Care Med"},{"key":"10.1124\/pr.111.005587_bib217","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/S0735-1097(02)02012-0","article-title":"Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival","volume":"40","author":"Sitbon","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"10.1124\/pr.111.005587_bib218","doi-asserted-by":"crossref","first-page":"611","DOI":"10.2165\/00003088-200847090-00004","article-title":"A clinical comparison of slow- and rapid-escalation treprostinil dosing regimens in patients with pulmonary hypertension","volume":"47","author":"Skoro-Sajer","year":"2008","journal-title":"Clin Pharmacokinet"},{"key":"10.1124\/pr.111.005587_bib219","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s10456-010-9192-y","article-title":"Treprostinil increases the number and angiogenic potential of endothelial progenitor cells in children with pulmonary hypertension","volume":"14","author":"Smadja","year":"2011","journal-title":"Angiogenesis"},{"key":"10.1124\/pr.111.005587_bib220","doi-asserted-by":"crossref","first-page":"S423","DOI":"10.1194\/jlr.R800094-JLR200","article-title":"Prostanoids in health and disease","volume":"50","author":"Smyth","year":"2009","journal-title":"J Lipid Res"},{"key":"10.1124\/pr.111.005587_bib221","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1136\/thx.2006.064097","article-title":"Long term imatinib treatment in pulmonary arterial hypertension","volume":"61","author":"Souza","year":"2006","journal-title":"Thorax"},{"key":"10.1124\/pr.111.005587_bib222","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1177\/0091270008324180","article-title":"Pharmacokinetics and safety of ambrisentan in combination with sildenafil in healthy volunteers","volume":"48","author":"Spence","year":"2008","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/pr.111.005587_bib223","doi-asserted-by":"crossref","first-page":"4962","DOI":"10.1002\/jps.21789","article-title":"No clinically relevant pharmacokinetic and safety interactions of ambrisentan in combination with tadalafil in healthy volunteers","volume":"98","author":"Spence","year":"2009","journal-title":"J Pharm Sci"},{"key":"10.1124\/pr.111.005587_bib224","doi-asserted-by":"crossref","first-page":"S67","DOI":"10.1038\/jp.2008.158","article-title":"Nitric oxide and beyond: new insights and therapies for pulmonary hypertension","volume":"28","author":"Steinhorn","year":"2008","journal-title":"J Perinatol"},{"key":"10.1124\/pr.111.005587_bib225","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.jpeds.2009.06.012","article-title":"Intravenous sildenafil in the treatment of neonates with persistent pulmonary hypertension","volume":"155","author":"Steinhorn","year":"2009","journal-title":"J Pediatr"},{"key":"10.1124\/pr.111.005587_bib226","doi-asserted-by":"crossref","first-page":"464","DOI":"10.7326\/0003-4819-114-6-464","article-title":"Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease?","volume":"114","author":"Stewart","year":"1991","journal-title":"Ann Intern Med"},{"key":"10.1124\/pr.111.005587_bib227","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1007\/s00134-003-2016-4","article-title":"Intravenous sildenafil and inhaled nitric oxide: a randomised trial in infants after cardiac surgery","volume":"29","author":"Stocker","year":"2003","journal-title":"Intensive Care Med"},{"key":"10.1124\/pr.111.005587_bib228","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1183\/09031936.00011308","article-title":"A randomised, controlled trial of bosentan in severe COPD","volume":"32","author":"Stolz","year":"2008","journal-title":"Eur Respir J"},{"key":"10.1124\/pr.111.005587_bib229","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1586\/erp.11.26","article-title":"Pharmacoeconomic evidence of bosentan for pulmonary arterial hypertension","volume":"11","author":"Strange","year":"2011","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"10.1124\/pr.111.005587_bib230","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1089\/1076327041348563","article-title":"Transplantation of endothelial progenitor cells into the lung to alleviate pulmonary hypertension in dogs","volume":"10","author":"Takahashi","year":"2004","journal-title":"Tissue Eng"},{"key":"10.1124\/pr.111.005587_bib231","doi-asserted-by":"crossref","DOI":"10.1007\/s00246-012-0180-4","article-title":"Initial experience with tadalafil in pediatric pulmonary arterial hypertension","author":"Takatsuki","year":"2012","journal-title":"Pediatr Cardiol"},{"key":"10.1124\/pr.111.005587_bib232","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s00395-004-0504-5","article-title":"Antiproliferative effect of sildenafil on human pulmonary artery smooth muscle cells","volume":"100","author":"Tantini","year":"2005","journal-title":"Basic Res Cardiol"},{"key":"10.1124\/pr.111.005587_bib233","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1378\/chest.129.3.683","article-title":"Safety and efficacy of IV treprostinil for pulmonary arterial hypertension: a prospective, multicenter, open-label, 12-week trial","volume":"129","author":"Tapson","year":"2006","journal-title":"Chest"},{"key":"10.1124\/pr.111.005587_bib234","first-page":"A1040","article-title":"Results of the FREEDOM\u2013C study: a pivotal study of oral treprostinil used adjunctively with an ERA and\/or PDE5-inhibitor for the treatment of PAH (Abstract)","volume":"179","author":"Tapson","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1124\/pr.111.005587_bib235","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s00392-009-0752-3","article-title":"Significant improvement of right ventricular function by imatinib mesylate in scleroderma-associated pulmonary arterial hypertension","volume":"98","author":"ten Freyhaus","year":"2009","journal-title":"Clin Res Cardiol"},{"key":"10.1124\/pr.111.005587_bib236","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1378\/chest.11-0969","article-title":"Validation of the pulmonary hypertension connection equation for survival prediction in pulmonary arterial hypertension","volume":"141","author":"Thenappan","year":"2012","journal-title":"Chest"},{"key":"10.1124\/pr.111.005587_bib237","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1183\/09031936.00072709","article-title":"Survival in pulmonary arterial hypertension: a reappraisal of the NIH risk stratification equation","volume":"35","author":"Thenappan","year":"2010","journal-title":"Eur Respir J"},{"key":"10.1124\/pr.111.005587_bib238","doi-asserted-by":"crossref","first-page":"e418","DOI":"10.1016\/j.thromres.2010.08.020","article-title":"Calibrated automated thrombography demonstrates hypercoagulability in patients with idiopathic pulmonary arterial hypertension","volume":"12","author":"Tournier","year":"2010","journal-title":"Thromb Res"},{"key":"10.1124\/pr.111.005587_bib239","unstructured":"Tracleer [U.S. package insert]. (2011) Actelion Pharmaceuticals US, Inc., South San Francisco, CA"},{"key":"10.1124\/pr.111.005587_bib240","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1164\/ajrccm.159.6.9804054","article-title":"Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension","volume":"159","author":"Tuder","year":"1999","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1124\/pr.111.005587_bib241","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1159\/000314271","article-title":"Platelet serotonin content and transpulmonary platelet serotonin gradient in patients with pulmonary hypertension","volume":"81","author":"Ulrich","year":"2011","journal-title":"Respiration"},{"key":"10.1124\/pr.111.005587_bib242","unstructured":"United States Food and Drug Administration (2001) Cardiovascular and Renal Drugs Advisory Committee. United Therapeutics Corporation Presentation: Efficacy of treprostinil. August 9\u201310, 2001. Available at: http:\/\/www.fda.gov\/ohrms\/dockets\/ac\/01\/slides\/3775s1.htm."},{"key":"10.1124\/pr.111.005587_bib243","unstructured":"United States Food and Drug Administration (2010) FDA Advisory Committee Briefing Document, Cardiovascular and Renal Drugs Advisory Committee, Center for Drug Evaluation and Research, 2010 Jul 29. Available at http:\/\/www.fda.gov\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/CardiovascularandRenalDrugsAdvisoryCommittee\/ucm220249.htm."},{"key":"10.1124\/pr.111.005587_bib244","unstructured":"United Therapeutics (2008) Freedom-C trial of oral treprostinil in pulmonary arterial hypertension fails to meet primary endpoint, 2008 Nov 17. Available at http:\/\/ir.unither.com\/releasedetail.cfm?ReleaseID=347887."},{"key":"10.1124\/pr.111.005587_bib245","unstructured":"United Therapeutics (2009) 2009 Annual Report. United Therapeutics, Silver Spring, MD. Available at http:\/\/ir.unither.com\/annuals.cfm."},{"key":"10.1124\/pr.111.005587_bib246","unstructured":"United Therapeutics (2011a) FREEDOM-C(2) trial of oral treprostinil in pulmonary arterial hypertension does not meet primary endpoint, 2011 Aug 24. Available at http:\/\/ir.unither.com\/releasedetail.cfm?ReleaseID=600804."},{"key":"10.1124\/pr.111.005587_bib247","unstructured":"United Therapeutics (2011b) FREEDOM-M trial of oral treprostinil in pulmonary arterial hypertension meets primary endpoint, 2011 Jun 6. Available at http:\/\/ir.unither.com\/releasedetail.cfm?ReleaseID=582786."},{"key":"10.1124\/pr.111.005587_bib248","unstructured":"United Therapeutics (2012) Oral treprostinil new drug application accepted by FDA for review, 2012 Feb 21. Available at http:\/\/ir.unither.com\/releasedetail.cfm?ReleaseID=650003."},{"key":"10.1124\/pr.111.005587_bib249","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.1365-2125.2010.03831.x","article-title":"Safety, tolerability and pharmacokinetics of an intravenous bolus of sildenafil in patients with pulmonary arterial hypertension","volume":"71","author":"Vachiery","year":"2011","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/pr.111.005587_bib250","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1177\/1753465808103499","article-title":"Effect of bosentan upon pulmonary hypertension in chronic obstructive pulmonary disease","volume":"3","author":"Valerio","year":"2009","journal-title":"Ther Adv Respir Dis"},{"key":"10.1124\/pr.111.005587_bib251","doi-asserted-by":"crossref","first-page":"113","DOI":"10.5414\/CPP44113","article-title":"Pharmacokinetic interaction between bosentan and the oral contraceptives norethisterone and ethinyl estradiol","volume":"44","author":"van Giersbergen","year":"2006","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1124\/pr.111.005587_bib252","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1055\/s-0029-1239496","article-title":"The use of sildenafil in persistent pulmonary hypertension of the newborn","volume":"27","author":"Vargas-Origel","year":"2010","journal-title":"Am J Perinatol"},{"key":"10.1124\/pr.111.005587_bib253","article-title":"Clinical pharmacokinetics and drug-drug interactions of endothelin receptor antagonists in pulmonary arterial hypertension","author":"Venitz","year":"2011","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/pr.111.005587_bib254","unstructured":"Ventavis [U.S. package insert]. (2011) Actelion Pharmaceuticals US, Inc., South San Francisco, CA."},{"key":"10.1124\/pr.111.005587_bib255","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.pupt.2011.01.002","article-title":"Differential response to intravenous prostacyclin analog therapy in patients with pulmonary arterial hypertension","volume":"24","author":"Walkey","year":"2011","journal-title":"Pulm Pharmacol Ther"},{"key":"10.1124\/pr.111.005587_bib256","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1016\/j.jacc.2006.12.037","article-title":"Transplantation of autologous endothelial progenitor cells may be beneficial in patients with idiopathic pulmonary arterial hypertension: a pilot randomized controlled trial","volume":"49","author":"Wang","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"10.1124\/pr.111.005587_bib257","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1038\/sj.bjc.6603170","article-title":"AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL","volume":"94","author":"Weisberg","year":"2006","journal-title":"Br J Cancer"},{"key":"10.1124\/pr.111.005587_bib258","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1164\/rccm.200411-1587OC","article-title":"Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells","volume":"172","author":"Wharton","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1124\/pr.111.005587_bib259","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1164\/rccm.200410-1411OC","article-title":"Sildenafil versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SERAPH) study","volume":"171","author":"Wilkins","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1124\/pr.111.005587_bib260","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1177\/0091270008315315","article-title":"Pharmacokinetic interaction between tadalafil and bosentan in healthy male subjects","volume":"48","author":"Wrishko","year":"2008","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/pr.111.005587_bib261","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1161\/HYPERTENSIONAHA.111.180968","article-title":"Sildenafil prevents and reverses transverse-tubule remodeling and Ca2+ handling dysfunction in right ventricle failure induced by pulmonary artery hypertension","volume":"59","author":"Xie","year":"2012","journal-title":"Hypertension"},{"key":"10.1124\/pr.111.005587_bib262","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1161\/CIRCRESAHA.109.209940","article-title":"Smad-dependent and smad-independent induction of id1 by prostacyclin analogues inhibits proliferation of pulmonary artery smooth muscle cells in vitro and in vivo","volume":"107","author":"Yang","year":"2010","journal-title":"Circ Res"},{"key":"10.1124\/pr.111.005587_bib263","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1097\/CCM.0B013E318165B7EA","article-title":"Autologous transplantation of bone marrow-derived endothelial progenitor cells attenuates monocrotaline-induced pulmonary arterial hypertension in rats","volume":"36","author":"Yip","year":"2008","journal-title":"Crit Care Med"},{"key":"10.1124\/pr.111.005587_bib264","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0002-9149(83)80035-6","article-title":"Comparative effects of nifedipine, verapamil, and diltiazem on experimental pulmonary hypertension","volume":"51","author":"Young","year":"1983","journal-title":"Am J Cardiol"},{"key":"10.1124\/pr.111.005587_bib265","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1161\/01.CIR.0000138104.83366.E9","article-title":"Outcomes in children with idiopathic pulmonary arterial hypertension","volume":"110","author":"Yung","year":"2004","journal-title":"Circulation"},{"key":"10.1124\/pr.111.005587_bib266","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1177\/1753465808101549","article-title":"Successful switch to sitaxsentan in a patient with HIV-related pulmonary arterial hypertension and late intolerance to nonselective endothelin receptor blockade","volume":"3","author":"Zac\u00e0","year":"2009","journal-title":"Ther Adv Respir Dis"},{"key":"10.1124\/pr.111.005587_bib267","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1016\/j.jacc.2010.08.612","article-title":"Myocardial remodeling is controlled by myocyte-targeted gene regulation of phosphodiesterase type 5","volume":"56","author":"Zhang","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1124\/pr.111.005587_bib268","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.ejphar.2011.08.015","article-title":"C-122, a novel antagonist of serotonin receptor 5-HT2B, prevents monocrotaline-induced pulmonary arterial hypertension in rats","volume":"670","author":"Zopf","year":"2011","journal-title":"Eur J Pharmacol"}],"container-title":["Pharmacological Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031699724010093?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031699724010093?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/pr.111.005587","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T10:14:26Z","timestamp":1739873666000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0031699724010093"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,7]]},"references-count":268,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,7]]}},"alternative-id":["S0031699724010093"],"URL":"https:\/\/doi.org\/10.1124\/pr.111.005587","relation":{},"ISSN":["0031-6997"],"issn-type":[{"value":"0031-6997","type":"print"}],"subject":[],"published":{"date-parts":[[2012,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Pharmacological Treatment of Pulmonary Arterial Hypertension","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/pr.111.005587","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2012 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}